Relmada Therapeutics (RLMD) Operating Expenses (2012 - 2026)

Relmada Therapeutics (RLMD) has 15 years of Operating Expenses data on file, last reported at $19.5 million in Q1 2026.

• Operating Expenses for Q1 2026 came in at $19.5 million, up 6.82% year-over-year; the trailing twelve-month figure through Mar 2026 was $60.3 million (down 23.73% YoY), and the FY2025 annual result was $59.1 million, down 29.55% from the prior year.
• Operating Expenses eased to $19.5 million in Q1 2026 per RLMD's latest filing, from $20.3 million in the prior quarter.
• Over five years, Operating Expenses peaked at $45.5 million in Q2 2022 and troughed at $10.2 million in Q2 2025.
• A 5-year average of $25.1 million and a median of $23.0 million in 2024 frame the typical range for Operating Expenses.
• The sharpest annual moves came in 2022 and 2025: Operating Expenses soared 71.99% in 2022, then plunged 55.12% in 2025.
• A 5-year view of Operating Expenses shows it stood at $38.7 million in 2022, then plunged by 30.68% to $26.8 million in 2023, then slipped by 28.9% to $19.1 million in 2024, then rose by 6.59% to $20.3 million in 2025, then decreased by 4.29% to $19.5 million in 2026.
• Business Quant data shows RLMD's Operating Expenses at $19.5 million in Q1 2026, $20.3 million in Q4 2025, and $10.3 million in Q3 2025.